

Plant Health Care plc

("PHC", the "Company" or "Plant Health Care")

Result of EGM and Update of French Myconate Trials

The Board of Plant Health Care, a leading provider of natural products for plants and soil, announces that at its Extraordinary General Meeting ("EGM") held today, the special resolutions proposed to shareholders (as set out in its notice to shareholders dated 10 April 2006) ("the Circular") were duly passed.

On 10 April 2006, the Company announced that it was to raise £6.5 million, before expenses, by way of a Placing of 10,000,000 new ordinary shares of 1p each ("Ordinary Shares") at a price of 65p per new Ordinary Share. These new Ordinary Shares were placed by Evolution Securities Limited with institutional investors. The Placing was conditional on, *inter alia*, Shareholder approval at an EGM. In addition, the authorities necessary for the allotment of the New Ordinary Shares pursuant to the Placing were to be sought at the EGM.

Following completion of the Placing, the issued share capital of the Company will increase to 40,180,222 fully paid Ordinary Shares and the new Ordinary Shares will represent 24.9 per cent. of the enlarged issued share capital.

Application has been made to the London Stock Exchange for the 10,000,000 new Ordinary Shares to be admitted to AIM, which is expected to become effective at 8.00 a.m. on 9 May 2006.

French Myconate Trials

The Board is also pleased to update shareholders on the completion of its Myconate trials in France. The results of these tests were of particular significance as not only did the corn crops show a spectacular increase in yield, but also because weather conditions were found to be less than ideal for the growing of corn.

Corn farming generally suits high temperature levels with high levels of rainfall. The three test areas in France, chosen specifically by the Group for these trials, exhibited a warm climate but one with a lower than average rainfall level. Irrigation controls in France are also strict, meaning the tests were carried out in conditions classed as "stressful" for the crops.

Yield improvement from the three sites ranged between 11.5% and 16%, significantly exceeding the average for the complete test programme carried out across the globe. This has subsequently led to an increase in interest for Myconate and the Group is in continued discussions with a consortium of French seed companies. The consortium has already installed trials throughout France with the results expected by the end of 2006.

-ends-

For enquiries:

Plant Health Care plc

Tel: 001 603 525 3702

John Brady, Chief Executive

Tavistock Communications

Jeremy Carey

Christian Taylor-Wilkinson

Tel: 020 7920 3150

Evolution Securities

Tim Worledge

Tim Redfern

Tel: 020 7071 4300